Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-15T17:17:16.552Z Has data issue: false hasContentIssue false
  • English
  • Français

Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone

Published online by Cambridge University Press:  21 February 2013

Enrica Di Rosa ,
Daniela Caldirola ,
Achille Motta  and
Giampaolo Perna
Enrica Di Rosa*
Affiliation:
Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy Department of Clinical Neuroscience, Hermanas Hospitalarias, FoRiPsi, Villa San Benedetto Menni, Albese con Cassano, Italy
Daniela Caldirola
Affiliation:
Department of Clinical Neuroscience, Hermanas Hospitalarias, FoRiPsi, Villa San Benedetto Menni, Albese con Cassano, Italy
Achille Motta
Affiliation:
Department of Clinical Neuroscience, Hermanas Hospitalarias, FoRiPsi, Villa San Benedetto Menni, Albese con Cassano, Italy
Giampaolo Perna
Affiliation:
Department of Clinical Neuroscience, Hermanas Hospitalarias, FoRiPsi, Villa San Benedetto Menni, Albese con Cassano, Italy Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, University of Miami, Miami, Florida, USA Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
*
Enrica Di Rosa, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Policlinico Universitario, via Consolare Valeria, Messina 198125, Italy. Tel: +00393333992601; Fax: +0039090695136; E‐mail: [email protected], [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Urgency, urinary incontinence and bowel disturbances are distressing side effects that have been observed during treatment with risperidone and other antipsychotics probably due to the receptor affinity profile. This occurrence can lead to poor compliance and therefore impair clinical outcome.

Method

We report the case of a 50 year‐old lady, who experienced urinary incontinence and diarrhoea, when switching from oral to injectable risperidone, which ceased when discontinuing the drug.

Results and conclusions

It should be taken into account that some side effects can be revealed when switching from oral to depot formulations due to non‐compliance to orals; nevertheless dose‐dependent mechanisms and individual metabolic variability must be considered when observing idiosyncratic reactions to drugs.

Keywords

atypical antipsychoticsinjectable resperidoneneuroleptic side effectspsychopharmacologyurinary incontinence
Type
Case Report
Information
Acta Neuropsychiatrica , Volume 25 , Issue 2 , April 2013 , pp. 119 - 121
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Sahoo, S, Manoj, K. Antipsychotic‐induced urinary dysfunction: anticholinergic effect or otherwise? BMJ Case Rep 2009. DOI: bcr02.2009.1547.Google Scholar
2Ambrosini, PJ. A pharmacological paradigm for urinary incontinence and enuresis. J Clin Psychopharmacol 1984;4:247–253.Google Scholar
3Ambrosini, PJ, Nurnberg, HG. Urinary incontinence and neuroleptics. Am J Psychiatry 1982;139:539.Google Scholar
4Sagar, R, Varghese, ST, Balhara, YP. Olanzapine‐induced double incontinence. Indian J Med Sci 2005;59:163–164.Google Scholar
5Benazzi, F. Urinary retention with fluoxetine–haloperidol combination in a young patient. Can J Psychiatry 1996;41:606–607.Google Scholar
6Kiruluta, HG, Andrews, K. Urinary incontinence secondary to drugs. Urology 1983;22:88–90.Google Scholar
7Myung‐Ji, L, Chul‐Eung, K. Use of aripiprazole in clozapine induced enuresis: report of two cases. J Korean Med Sci 2010;25:333–335.Google Scholar
8Herguner, S, Mukaddes, NM. Risperidone‐induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1085–1086.Google Scholar
9Fraser, MO, Chancellor, MB. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int 2003;91:743–748.Google Scholar
10Deeks, ED. Risperidone long‐acting injection in bipolar I disorder. Drugs 2010;70:1001.012.Google Scholar
11Vera, PL, Miranda‐Sousa, A, Nadelhaft, I. Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol 2001;1:4.Google Scholar
12Kirshner, A, Davis, RR. Priapism associated with the switch from oral to injectable risperidone. J Clin Psychopharmacol 2006;26:626–628.Google Scholar
13Hendset, M, Molden, E, Refsum, H, Hermann, M. Impact of CYP2D6 genotype on steady‐state serum concentration of risperidone and 9 hydroxyrisperidone in patients using long‐acting injectable risperidone. J Clin Psychopharmacol 2009;29:537–541.Google Scholar
14de Leon, J, Susce, MT, Pan, RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuations. J Clin Psychiatry 2005;66:15–27.Google Scholar
15Smith, EM, Iftikar, FI, Higgins, S et al. In vitro inhibition of cytochrome P450‐mediated reactions by gemfibrozil, erythromycin, ciprofloxacin and fluoxetine in fish liver microsomes. Aquat Toxicol 2012;109:259–266.Google Scholar
16Desta, Z, Kerbusch, T, Flockhart, DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10–20.Google Scholar
17Bruce, MA, Hall, SD, Haehner‐Daniels, BD et al. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001;29:1023–1028.Google Scholar
18Hersh, EV, Moore, PA. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 2004;135:298–311.Google Scholar
19Ishak, KJ, Tan, Y, Glass, J et al. Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case‐control study in patients with schizophrenia. Clin Ther 2008;30:1.Google Scholar